Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $9.54, but opened at $9.97. Telix Pharmaceuticals shares last traded at $9.71, with a volume of 37,146 shares trading hands.
Analysts Set New Price Targets
Several analysts have recently weighed in on TLX shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. Wedbush reaffirmed an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. HC Wainwright lowered their target price on shares of Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. Finally, Citigroup started coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a "buy" rating and a $22.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Telix Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $21.00.
Read Our Latest Stock Report on Telix Pharmaceuticals
Telix Pharmaceuticals Trading Up 3.5%
The business's fifty day moving average is $10.39 and its 200 day moving average is $14.25.
Institutional Trading of Telix Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. Private Advisor Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $170,000. ABC Arbitrage SA purchased a new stake in shares of Telix Pharmaceuticals in the first quarter valued at about $451,000. Russell Investments Group Ltd. purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $975,000. Jane Street Group LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $564,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $213,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
